By Fineline Cube 
US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing by 6.5% year-on-year (YOY) to USD 15.42 billion. CEO Robert A. Michael highlighted that the results “exceeding our expectations” and announced a raise in the firm’s full-year guidance by USD 1.5 billion to USD 60.5 billion.
Immunology Portfolio Drives Growth
The immunology portfolio recorded a 9.2% sales increase to USD 7.63 billion, supported by significant growth from two key autoimmune disease drugs:
- Skyrizi (risankizumab): Targeting interleukin-23 (IL-23), sales surged by 61.8% to USD 4.42 billion.
- Rinvoq (upadacitinib): A JAK inhibitor, sales rose by 41.2% to USD 2.03 billion.
These gains helped offset the 58.2% sales decline for off-patent Humira (adalimumab), which recorded USD 1.18 billion in sales.
Neuroscience Portfolio Highlights
The neuroscience portfolio saw a 23% increase in sales to USD 2.683 billion, driven by:
- Vraylar (cariprazine): Anti-depressant sales up 16.3% to USD 900 million.
- Botox Therapeutic: Botulinum toxin sales up 14.2% to USD 928 million.
- Ubrelvy (ubrogepant): Migraine treatment sales up 47.2% to USD 338 million.
- Qulipta (atogepant): Migraine drug revenues up 76.9% to USD 267 million.
Oncology and Aesthetics Portfolio
Oncology sales rose by 2.4% to USD 1.68 billion, while the aesthetics portfolio experienced an 8.1% decrease to USD 1.279 billion.
R&D Highlights
During the earnings call, AbbVie emphasized several key R&D milestones:
- Approval of Emrelis (telisotuzumab vedotin), a c-Met targeted antibody-drug conjugate (ADC) for non-squamous non-small cell lung cancer.
- Approval of Rinvoq (upadacitinib) for giant cell arteritis.
- First regulatory submission for trenibotulinumtoxinE (TrenibotE) for moderate to severe glabellar lines.
- Strong Phase III data from Rinvoq in alopecia areata.-Fineline Info & Tech